At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 118 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Response Variability in Treatment Resistant Depression - an Ancillary Study to "Sequenced Treatment Alternatives to Relieve Depression (STAR*D)"
In Brief
A Phase 4 clinical trial evaluating Escitalopram and Sertraline for Depression. Completed, enrolled 118 participants across 3 sites.
Detailed Summary
This study will examine how brain activity is affected by antidepressant treatment and how changes in brain activity relate to treatment response in people with depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedSep 2006
Primary CompletionJun 2007
Study CompletionMar 2008
TodayJul 2026
First PostedSep 13, 2006
Enrollment StartJan 1, 2005
Primary CompletionJun 1, 2007
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.8 years ago
Interventions
Escitalopramdrug
Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
Sertralinedrug
Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.